Share ownership Revolution Medicines, Inc.

RVMD

US76155X1000

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 17:56:11 13/03/2026 GMT			5-day change	1st Jan Change
96.14 ^USD	+1.12%		-2.17%	+20.86%

03-04	Revolution Medicines Insider Sold Shares Worth $3,644,354, According to a Recent SEC Filing	MT
03-03	Revolution Medicines, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 09:50 AM

Share class: Revolution Medicines, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	189,884,424	164,633,699 ( 86.7 %)	5,560,000 ( 2.928 %)	86.7 %

Major shareholders: Revolution Medicines, Inc.

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 8.437 %	16,719,886	8.437 %	1 706 M $
Farallon Capital Management LLC 7.359 %	14,582,796	7.359 %	1 488 M $
Janus Henderson Investors US LLC 6.208 %	12,303,502	6.208 %	1 255 M $
Baker Bros. Advisors LP 4.771 %	9,455,357	4.771 %	965 M $
Fidelity Management & Research Co. LLC 4.333 %	8,586,477	4.333 %	876 M $
BlackRock Advisors LLC 4.237 %	8,396,348	4.237 %	857 M $
Nextech Invest AG 3.836 %	7,601,087	3.836 %	775 M $
Wellington Trust Co., NA 3.526 %	6,987,639	3.526 %	713 M $
Paradigm BioCapital Advisors LP 3.353 %	6,644,403	3.353 %	678 M $
Bellevue Asset Management AG 2.526 %	5,005,719	2.526 %	511 M $
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
T Rowe Price Associates, Inc. (13F Subfiler) -	4,000,651	-	9 M $
LMR Partners LLP -	3,151,705	-	7 M $
D.E. Shaw & Co., Inc. -	1,454,895	-	3 M $
Aristeia Capital LLC -	624,935	-	1 M $
City National Rochdale LLC -	507,997	-	1 M $
Adage Capital Partners GP LLC -	500,000	-	1 M $
Lunate Capital Ltd. -	450,000	-	972 000 $
TD Asset Management, Inc. (13F Subfiler) -	411,156	-	888 097 $
Soros Capital Management LLC -	364,824	-	788 020 $
Soros Capital Management LLC -	364,824	-	788 020 $
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	91.03%
Other	11.9%
Individuals	2.32%
State Street Corp.	2.07%
Alphabet, Inc.	1.69%
Polar Capital Holdings Plc	1.02%
Schweizerische Nationalbank	0.14%
Manulife Financial Corp.	0.09%
The Bank of Nova Scotia	0.06%
SEI Investments Co.	0.05%
Governments	0.04%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	90.62%
Switzerland	7.09%
United Kingdom	4.84%
Individuals	2.32%
United Arab Emirates	1.34%
Norway	1.25%
Luxembourg	0.7%
Australia	0.66%
Hong Kong	0.46%
Canada	0.45%
Germany	0.23%
China	0.13%
Sweden	0.08%
Ireland	0.07%
Japan	0.03%
Singapore	0.03%
Austria	0.03%
Israel	0.03%
Puerto Rico	0.01%
South Korea	0.01%
Spain	0.01%
France	0.01%
Taiwan	0.01%

Based on 1000 largest holdings

Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Companyâ€™s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. Its RAS Companion Inhibitors are designed primarily for combination treatment strategies centered on its RAS(ON) Inhibitors. The Companyâ€™s RAS(ON) Inhibitors RMC-6236 RMC-6291 and RMC-9805 are in clinical development. RMC-6236, its RASMULTI(ON) inhibitor, is designed as a potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants, including cancer drivers.

Employees

883

Sector

Biotechnology & Medical Research

More about the company